CareDx CFO Keith Kennedy exercises 2,097 options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CareDx, Inc. CFO & COO Keith Kennedy exercised options to acquire 2,097 common shares on November 12, 2026, at an exercise price of $29.43 per share. He also reported two sales that day: 800 shares at a weighted-average $78.7825 per share and 1,297 shares at a weighted-average $79.6068 per share. Both sales were made under a Rule 10b5-1 trading plan adopted August 6, 2026. The option position following the exercise was reported as 46,132 shares.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F4 | 2,097 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,097 | $29.43 | $62K |
| Sale | Common Stock F1, F2 | 800 | $78.7825 | $63K |
| Sale | Common Stock F1, F3 | 1,297 | $79.6068 | $103K |
Footnotes (4)
- F1. The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 6, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $79.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.29 to $79.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. 1/4th of the shares subject to this option shall vest on September 12, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter through September 30, 2028.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Employee Stock Option (right to buy) technical
vest technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What option exercise did CareDx CFO Keith Kennedy report?
AI-generated analysis. How Rhea-AI works. Not financial advice.